Orforglipron: what the GLP-1 pill is, and what the evidence shows

Orforglipron (brand name Foundayo) is a once-daily oral, non-peptide GLP-1 receptor agonist — a small molecule that activates the same appetite-and-glucose receptor as the injectable GLP-1 medicines, but in a tablet. The U.S. FDA approved it on April 1, 2026 for weight management in adults with obesity, or with overweight plus at least one weight-related condition.

This page describes what the molecule is, what its approval and trials actually show, and how an oral GLP-1 differs from the injections. It contains no doses. It describes evidence; it does not give individual medical advice.

What is orforglipron?

Orforglipron is a small-molecule (non-peptide) GLP-1 receptor agonist taken by mouth once a day. “Non-peptide” is the key engineering point: older GLP-1 drugs are peptides that the gut breaks down, which is why most are injected and why the one earlier oral GLP-1 peptide (oral semaglutide, sold as Rybelsus) must be taken on an empty stomach with strict food-and-water rules. Because orforglipron is a chemically different small molecule, its label states it can be taken any time of day, with or without food or water — a practical distinction for daily life. It is sold under the brand name Foundayo and made by Eli Lilly.

Is orforglipron FDA-approved? What is it approved for?

Yes. On April 1, 2026, the FDA approved orforglipron (Foundayo) for chronic weight management — used with a reduced-calorie diet and increased physical activity — in adults with obesity, or adults with overweight who also have at least one weight-related condition such as high blood pressure or type 2 diabetes. It was the first new molecular entity cleared under the FDA’s National Priority Voucher program. With approval, orforglipron moves onto the top of the Evidence Ladder for its approved weight-management use (an approved drug used as approved). The grade on this page stays at supported-but-limited for a deliberate reason: the human evidence is real and from large randomized trials, but it is recent and narrow — roughly 72-week trials, no published long-term cardiovascular-outcome results yet, and limited real-world or head-to-head data against the established injectables.

What did the phase-3 trials show?

The approval rests on the ATTAIN phase-3 program. Two pivotal trials anchor the weight-loss evidence:

• ATTAIN-1 (3,127 adults with obesity or overweight, without diabetes), published in the New England Journal of Medicine (2025). At 72 weeks the highest studied dose produced about 11–12% average body-weight loss (the exact figure depends on the analysis method/estimand), versus about 2% on placebo. Roughly 60% of people on the highest dose lost at least 10% of their body weight.
• ATTAIN-2 (adults with overweight or obesity and type 2 diabetes), published in The Lancet (2025). The highest dose produced about 10% average weight loss at 72 weeks, alongside meaningful improvements in blood-sugar (HbA1c) measures.

Across both trials the side-effect profile matched the GLP-1 class: gastrointestinal events (nausea, diarrhea, vomiting, constipation) were the most common, mostly mild to moderate, and tended to cluster around dose increases. This is consistent, large-trial human evidence — the strong end of the ladder for what it directly measured.

How does an oral GLP-1 differ from the injections?

The headline difference is route and convenience, not a proven advantage in long-term outcomes. A pill removes needles and the cold-chain storage that injectables need. But the injectable dual agonist tirzepatide (Zepbound/Mounjaro) and injectable semaglutide (Wegovy/Ozempic) have larger and longer human track records, including a published cardiovascular-outcome trial for semaglutide. Cross-trial weight-loss numbers are not a fair head-to-head; different trials, populations, and timeframes.

	Orforglipron (Foundayo)	Oral semaglutide (Rybelsus)	Injectable GLP-1 / dual agonists (e.g. Wegovy, Zepbound)
Form	Once-daily pill	Once-daily pill	Once-weekly injection
Molecule type	Small molecule, non-peptide	Peptide	Peptide
Food/water rules	None per label	Strict empty-stomach + water + wait	Not applicable
Approved here for	Weight management (2026)	Type 2 diabetes (weight version varies by market)	Weight management and/or diabetes
Human track record	Recent (approved 2026)	Several years	Most extensive; CV-outcome data for semaglutide
Evidence grade (this site)	Supported-but-limited	Established (for its use)	Established

Does orforglipron carry a boxed warning?

Yes. Like other GLP-1 receptor agonists, the Foundayo label carries a boxed warning about thyroid C-cell tumors. The label notes orforglipron did not produce these tumors in rodents and the human relevance is undetermined — but it is contraindicated in people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). As with other GLP-1 medicines, the label also addresses risks such as pancreatitis and gallbladder disease. Read the full label and discuss your own history with a clinician.

Frequently asked questions

Is orforglipron the same as Ozempic or Wegovy in a pill? No. Those are semaglutide (a peptide). Orforglipron is a different, non-peptide molecule. It acts on the same GLP-1 receptor, but it is not “semaglutide in pill form.”

Is it approved for type 2 diabetes? The 2026 approval covered in this page is for weight management. Orforglipron has also been studied in type 2 diabetes (the ATTAIN-2 and separate diabetes trials), but check the current label for exactly which uses are approved where.

How does its weight loss compare to the injections? In its own trials the highest dose averaged roughly 11–12% at 72 weeks. That is substantial, but you cannot directly rank it against tirzepatide or semaglutide from separate trials — only head-to-head studies can do that fairly.

Are the side effects different because it’s a pill? The trial side-effect profile was the familiar GLP-1 pattern, dominated by gastrointestinal symptoms that were mostly mild-to-moderate and dose-related.

Questions to ask a clinician

• Given my history and goals, is an oral GLP-1 a reasonable option, or is an injectable with a longer track record a better fit?
• Do I have any personal or family history (such as medullary thyroid cancer or MEN 2) that would rule this out?
• What is the plan for managing nausea or other GI symptoms in the early weeks?
• How will we monitor progress, and what would make us pause, change, or stop?
• If I could become pregnant: what should I know about contraception and timing before conceiving?

Red flags / when to seek care

These are not “ride-it-out” symptoms — contact a clinician promptly, and seek urgent care for the severe versions:

• Severe or persistent abdominal pain, especially pain radiating to the back with repeated vomiting — a possible sign of pancreatitis.
• Upper-right abdominal pain, fever, or yellowing of the skin or eyes — possible gallbladder disease.
• A swollen neck lump, hoarseness, or trouble swallowing — report promptly given the thyroid warning.
• Signs of dehydration from prolonged vomiting or diarrhea — dizziness, very dark or scant urine, confusion.

If something feels genuinely wrong in your body, that is not a claim to grade on a ladder — it is a reason to call.